Hopewell Therapeutics Sublicenses Tissue-Targeting Lipid Nanoparticles to Foxcroft for Novel Cancer Vaccine Development
Key Insights
Hopewell Therapeutics (search) has entered its first commercial sublicense agreement with Foxcroft Therapeutics (search), granting global access to proprietary tissue-targeting lipid nanoparticles (search) for cancer (search) vaccine delivery.
The collaboration builds on Foxcroft's exclusive license to novel tumor lysate-based cancer vaccine (search) technology from Tufts University, with Hopewell's LNPs serving as the preferred delivery system.
Foxcroft plans to initiate large mammal canine trials in mid-2026 using Hopewell's tissue-targeting LNPs, marking a significant step toward human clinical testing.
Hopewell Therapeutics (search), a Boston-based next-generation lipid nanoparticle company, has announced its first commercial sublicense agreement with Foxcroft Therapeutics (search) for the development of novel cancer (search) vaccines. The global sublicense grants Foxcroft access to Hopewell's proprietary tissue-targeting lipid nanoparticles (search) (ttLNPs) as delivery vehicles for cancer vaccine technology licensed from Tufts University.
Strategic Partnership for Cancer Vaccine Development
The collaboration represents a significant milestone for Hopewell, marking the company's inaugural commercial license of its ttLNP technology. Foxcroft obtained exclusive global rights to the underlying cancer (search) vaccine technology from Tufts University in September 2025, following the publication of foundational research by Dr. Qiaobing Xu, Hopewell's Founder and President.
In February 2025, Dr. Xu authored a paper entitled "Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates," which described a novel tumor lysate-based cancer vaccine (search) delivered through LNPs that target lymph nodes (search). This research formed the scientific foundation for Foxcroft's licensed technology.
Advanced Delivery Platform Technology
Hopewell's ttLNPs are designed to target multiple tissues throughout the body, including the lung, brain, bone marrow, ovaries, spleen, lymph nodes (search), kidneys, liver, and other vital organs. Pre-clinical testing has demonstrated that Hopewell's ttLNPs perform more effectively than other LNPs currently available in the market.
The company is developing its ttLNP platform for a broad range of clinical and therapeutic applications, including vaccines, gene therapies, immune-oncology, and pulmonary therapies. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and established partnerships with several industry-leading companies.
Clinical Development Timeline
Foxcroft plans to conduct confirmatory testing of vaccine formulations in large mammal trials, beginning with a canine clinical trial expected to commence in mid-2026. This represents a critical step in the development pathway toward human clinical testing of the novel cancer (search) vaccine technology.
"Hopewell is thrilled to announce the first sublicense of its ttLNP technology in the exciting field of cancer (search) vaccines," commented Dr. Xu. "We look forward to supporting Foxcroft to bring this important anti-cancer therapy to human testing as quickly as possible."
Financial Terms and Commercial Potential
The sublicense agreement includes substantial financial commitments, featuring a significant non-refundable upfront license fee, royalties on net sales, regulatory milestone payments, and up to $100 million in sales-based milestone payments. These terms reflect the commercial potential and strategic value of the partnership.
Foxcroft's management expressed confidence in the collaboration, stating, "We recognize that Hopewell's LNP library provides superior targeted delivery solutions for a number of clinical and therapeutic applications, including our vaccine. Over the months ahead, we are excited to work further with the Hopewell team to further evaluate the sublicensed LNPs."
Company Profiles
Foxcroft Therapeutics (search), founded in 2025 by investors from the USA and Thailand, focuses on immune-oncology based vaccines and is actively assembling strategic intellectual property to develop state-of-the-art therapies for unmet medical needs.
Hopewell Therapeutics (search) is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells. The company is developing its own internal pipeline while exploring the potential of its ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders.